NCT05782166

Brief Summary

The practice of betel quid chewing is known as the top 3 causes of oral cancers in Malaysia. The devastating part among Malaysians are that more than 50% of these cancer patients present at a later stage of this disease necessitating a massive surgical procedure and a costly oncological treatment to remove the tumour and restore the vital structures in the head and neck regions of the patients. In 2010, World Health Organisation recognised that the users of betel quid are having a 'Dependency Syndrome' similar to that of a cigarette smoking. Since then, much research has been focussed upon the 'addictive nature' and the cessation of this ill-health behaviour. Malaysia's current plight is its strikingly high prevalence of betel quid users within its high-risk communities. The other challenge is the widely scattered high-risk communities across the diverse geography, locality, ethnicity, culture and native languages across the country that make cessation not an easy task but an uphill battle. The latest available report in 2011 showed that the females in Sabah and Sarawak's indigenous communities presented with a prevalence of 28.4% being current chewers. This prevalence was way greater than the global prevalence of 10-20% of betel quid chewers reported worldwide. The female predominance among the betel quid users in Malaysia is another matter of concern as studies had claimed that females are less likely to cease chewing habit compared to their male counterparts. Fortunately, in 2015, a feasibility study was conducted to adapt an intensive smoking cessation intervention to cater for betel quid chewers which received a high cessation rate of 65%. Later in 2018, researchers incorporated a saliva test to assess the effectiveness of a group-based intensive betel quid cessation program which also yielded a high cessation rate of 38% among the participants. Since there is no existing betel quid cessation intervention in Malaysia, this study aims to adapt a betel quid cessation program for a high-risk community in Malaysia. This study hypothesised that the intervention group will produce a significantly greater cessation rate compared to the control group at the 3-months follow-up assessment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
92

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2024

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 12, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 23, 2023

Completed
10 months until next milestone

Study Start

First participant enrolled

January 2, 2024

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2024

Completed
Last Updated

December 6, 2023

Status Verified

November 1, 2023

Enrollment Period

6 months

First QC Date

March 12, 2023

Last Update Submit

November 29, 2023

Conditions

Keywords

Betel QuidCessation ProgramEffectiveness

Outcome Measures

Primary Outcomes (2)

  • Change in the number of participants who self-reported that they had quitted betel quid chewing behaviour from baseline at Day-22

    A follow-up questionnaire will be used to assess the self-reported cessation rate. This rate will represent the immediate cessation prevalence after the program

    Day-22

  • Change in the number of participants who self-reported that they had quitted betel quid chewing behaviour from baseline at Month-3

    A follow-up questionnaire will be used to assess the self-reported cessation rate. This rate will represent the intermediate-term cessation prevalence of the program

    Month-3

Secondary Outcomes (2)

  • Change in the levels of areca nut biomarkers in the saliva sample from baseline at Day-22

    Day-22

  • Change in the levels of areca nut biomarkers in the saliva sample from baseline at Month-3

    Month-3

Study Arms (2)

Betel Quid Cessation via Educational Booklet

PLACEBO COMPARATOR

Participants will be given only an educational booklet on screening day (Day-1) and will be followed up on Day-22 and Month-3 to assess their current chewing status and other related parameters.

Behavioral: Betel Quid Educational Booklet

Betel Quid Cessation via Educational Booklet & Intervention Module

EXPERIMENTAL

Participants will undergo a 5-intervention sessions which will enhance their self-efficacy o quit their chewing behaviour. During the intervention sessions, they will be guided on how to monitor their chewing triggers, the lifestyle changes that they can potentially make, how to tap on their social support system to aid in their cessation efforts and others. The intervention will last for 22 days and a follow-up session will be made on Month-3.

Behavioral: Betel Quid Educational BookletBehavioral: Betel Quid Cessation Intervention Module

Interventions

Eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained. Participants will be given an educational booklet containing general information regarding betel quid and areca nut, risk associated with betel quid chewing behaviour, cessation strategies that are modeled after tobacco cessation and some relevant researcher's contact details. Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour.

Betel Quid Cessation via Educational BookletBetel Quid Cessation via Educational Booklet & Intervention Module

All eligible and consented participants will be interviewed for baseline questionnaire completion. Details regarding participants' demographics, betel quid chewing behaviours, betel quid composition, betel quid dependency levels, reasons for chewing, readiness and self-perceived barriers to quit will be obtained. Saliva samples will be obtained. An interactive, educational talk will be given regarding the content of the educational booklet. Participants will undergo a 5-intervention sessions cessation program (M-BENIT) and will be given topical worksheets on every session to monitor their triggers, lifestyle changes, social support system and others. Participants will be followed up at Day-22 and Month-3 for information regarding compliance, current chewing status, number of habit cut-down (quid/day), total number of sessions attended and current betel quid composition. Saliva samples will be taken during follow-ups for the cessation verification of participant's chewing behaviour.

Betel Quid Cessation via Educational Booklet & Intervention Module

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • A self-reported betel quid chewer who has been practising chewing habit for the past 6 months with atleast 2-3 chewing episodes per week. The ingredient of betel quid must include areca nut without or without smokeless tobacco.
  • Age of participant must be 18 years old and above
  • Participants must be residing in study location (Kota Belud, Sabah)
  • Ability to comprehend, converse and read in Bahasa Melayu and their local language (Bajau)
  • Participants who are able to provide written consent and agree to comply with all protocol-specified procedures such as providing saliva samples, participating in five 1-2 hours sessions of intervention over 22 days and agree to attend follow-up session on the third month

You may not qualify if:

  • Non-Malaysian citizen
  • Participants who are not willing to quit the betel quid chewing habit at the time of the study
  • Women chewers who are pregnant or nursing at the time of study
  • Individuals with psychiatric illness or special social situations that would limit their compliance with study requirements

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

State Dental Health Department

Kota Kinabalu, Sabah, 88590, Malaysia

Location

Related Publications (71)

  • Al-Rmalli SW, Jenkins RO, Haris PI. Betel quid chewing elevates human exposure to arsenic, cadmium and lead. J Hazard Mater. 2011 Jun 15;190(1-3):69-74. doi: 10.1016/j.jhazmat.2011.02.068. Epub 2011 Feb 26.

    PMID: 21440366BACKGROUND
  • Asthana S, Greig NH, Holloway HW, Raffaele KC, Berardi A, Schapiro MB, Rapoport SI, Soncrant TT. Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease. Clin Pharmacol Ther. 1996 Sep;60(3):276-82. doi: 10.1016/S0009-9236(96)90054-5.

    PMID: 8841150BACKGROUND
  • Barker DJ. Fetal origins of coronary heart disease. BMJ. 1995 Jul 15;311(6998):171-4. doi: 10.1136/bmj.311.6998.171.

    PMID: 7613432BACKGROUND
  • Chatterjee A, Deb S. Genotoxic effect of arecoline given either by the peritoneal or oral route in murine bone marrow cells and the influence of N-acetylcysteine. Cancer Lett. 1999 May 3;139(1):23-31. doi: 10.1016/s0304-3835(98)00364-4.

    PMID: 10408905BACKGROUND
  • Bhat SJ, Blank MD, Balster RL, Nichter M, Nichter M. Areca nut dependence among chewers in a South Indian community who do not also use tobacco. Addiction. 2010 Jul;105(7):1303-10. doi: 10.1111/j.1360-0443.2010.02952.x.

    PMID: 20642513BACKGROUND
  • Boucher BJ, Ewen SW, Stowers JM. Betel nut (Areca catechu) consumption and the induction of glucose intolerance in adult CD1 mice and in their F1 and F2 offspring. Diabetologia. 1994 Jan;37(1):49-55. doi: 10.1007/BF00428777.

    PMID: 8150230BACKGROUND
  • Brown, R. A. (2003). Intensive behavioral treatment. The tobacco dependence treatment handbook: A guide to best practices, 118-177.

    BACKGROUND
  • Das A, Orlan E, Duncan K, Thomas H, Ndumele A, Ilbawi A, Parascandola M. Areca Nut and Betel Quid Control Interventions: Halting the Epidemic. Subst Use Misuse. 2020;55(9):1552-1559. doi: 10.1080/10826084.2019.1686022.

    PMID: 32569544BACKGROUND
  • Deng JF, Ger J, Tsai WJ, Kao WF, Yang CC. Acute toxicities of betel nut: rare but probably overlooked events. J Toxicol Clin Toxicol. 2001;39(4):355-60. doi: 10.1081/clt-100105155.

    PMID: 11527229BACKGROUND
  • Franke AA, Mendez AJ, Lai JF, Arat-Cabading C, Li X, Custer LJ. Composition of betel specific chemicals in saliva during betel chewing for the identification of biomarkers. Food Chem Toxicol. 2015 Jun;80:241-246. doi: 10.1016/j.fct.2015.03.012. Epub 2015 Mar 19.

    PMID: 25797484BACKGROUND
  • Franke AA, Li X, Lai JF. Pilot study of the pharmacokinetics of betel nut and betel quid biomarkers in saliva, urine, and hair of betel consumers. Drug Test Anal. 2016 Oct;8(10):1095-1099. doi: 10.1002/dta.1912. Epub 2015 Dec 1.

    PMID: 26619803BACKGROUND
  • Franke AA, Li X, Herzog TA, Paulino YC, Badowski G, Wilkens LR, Lai JF. Salivary Areca and tobacco alkaloids for bioverification in the Betel Nut Intervention Trial. Drug Test Anal. 2023 Jan;15(1):58-65. doi: 10.1002/dta.3364. Epub 2022 Oct 2.

    PMID: 36057968BACKGROUND
  • Ghani WM, Razak IA, Yang YH, Talib NA, Ikeda N, Axell T, Gupta PC, Handa Y, Abdullah N, Zain RB. Factors affecting commencement and cessation of betel quid chewing behaviour in Malaysian adults. BMC Public Health. 2011 Feb 7;11:82. doi: 10.1186/1471-2458-11-82.

    PMID: 21294919BACKGROUND
  • Giri S, Idle JR, Chen C, Zabriskie TM, Krausz KW, Gonzalez FJ. A metabolomic approach to the metabolism of the areca nut alkaloids arecoline and arecaidine in the mouse. Chem Res Toxicol. 2006 Jun;19(6):818-27. doi: 10.1021/tx0600402.

    PMID: 16780361BACKGROUND
  • Guidelines Primary Prevention and Early Detection of Oral Potentially Malignant Disorders and Oral Cancers. (2018). Oral Health Program Ministry of Health Malaysia.

    BACKGROUND
  • Gupta PC, Warnakulasuriya S. Global epidemiology of areca nut usage. Addict Biol. 2002 Jan;7(1):77-83. doi: 10.1080/13556210020091437.

    PMID: 11900626BACKGROUND
  • Hahn S, Puffer S, Torgerson DJ, Watson J. Methodological bias in cluster randomised trials. BMC Med Res Methodol. 2005 Mar 2;5:10. doi: 10.1186/1471-2288-5-10.

    PMID: 15743523BACKGROUND
  • Herzog TA, Murphy KL, Little MA, Suguitan GS, Pokhrel P, Kawamoto CT. The Betel Quid Dependence Scale: replication and extension in a Guamanian sample. Drug Alcohol Depend. 2014 May 1;138:154-60. doi: 10.1016/j.drugalcdep.2014.02.022. Epub 2014 Feb 26.

    PMID: 24629627BACKGROUND
  • Herzog, T. A, Zain, R. B, Ghani WN et al. (2014). Betel quid chewing (BQC) cessation multi-country study: Malaysia. [Unpublished manuscript].

    BACKGROUND
  • Herzog, T. A. (2022). Betel Nut Research in the Pacific [PowerPoint slides]. University of Hawai'i Cancer Center Honolulu, Hawai'i, USA.

    BACKGROUND
  • Huang, J. L., & McLeish, M. J. (1989). High-performance liquid chromatographic determination of the alkaloids in betel nut. Journal of Chromatography A, 475(2), 447-450.

    BACKGROUND
  • Hung DZ, Deng JF. Acute myocardial infarction temporally related to betel nut chewing. Vet Hum Toxicol. 1998 Feb;40(1):25-8.

    PMID: 9467205BACKGROUND
  • Hung CR. Effect of lysozyme chloride on betel quid chewing aggravated gastric oxidative stress and hemorrhagic ulcer in diabetic rats. World J Gastroenterol. 2005 Oct 7;11(37):5853-8. doi: 10.3748/wjg.v11.i37.5853.

    PMID: 16270397BACKGROUND
  • Jeng JH, Kuo ML, Hahn LJ, Kuo MY. Genotoxic and non-genotoxic effects of betel quid ingredients on oral mucosal fibroblasts in vitro. J Dent Res. 1994 May;73(5):1043-9. doi: 10.1177/00220345940730050501.

    PMID: 8006230BACKGROUND
  • Javed F, Chotai M, Mehmood A, Almas K. Oral mucosal disorders associated with habitual gutka usage: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Jun;109(6):857-64. doi: 10.1016/j.tripleo.2009.12.038. Epub 2010 Apr 9.

    PMID: 20382045BACKGROUND
  • Kuo MY, Jeng JH, Chiang CP, Hahn LJ. Mutations of Ki-ras oncogene codon 12 in betel quid chewing-related human oral squamous cell carcinoma in Taiwan. J Oral Pathol Med. 1994 Feb;23(2):70-4. doi: 10.1111/j.1600-0714.1994.tb00259.x.

    PMID: 8164156BACKGROUND
  • Lee CH, Lee JM, Wu DC, Hsu HK, Kao EL, Huang HL, Wang TN, Huang MC, Wu MT. Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. Int J Cancer. 2005 Jan 20;113(3):475-82. doi: 10.1002/ijc.20619.

    PMID: 15455377BACKGROUND
  • Lee CH, Ko AM, Yen CF, Chu KS, Gao YJ, Warnakulasuriya S, Sunarjo, Ibrahim SO, Zain RB, Patrick WK, Ko YC. Betel-quid dependence and oral potentially malignant disorders in six Asian countries. Br J Psychiatry. 2012 Nov;201(5):383-91. doi: 10.1192/bjp.bp.111.107961. Epub 2012 Sep 20.

    PMID: 22995631BACKGROUND
  • Lee CY, Chang CS, Shieh TY, Chang YY. Development and validation of a self-rating scale for betel quid chewers based on a male-prisoner population in Taiwan: the Betel Quid Dependence Scale. Drug Alcohol Depend. 2012 Feb 1;121(1-2):18-22. doi: 10.1016/j.drugalcdep.2011.07.027. Epub 2011 Sep 28.

    PMID: 21955360BACKGROUND
  • Lin SK, Chang YJ, Ryu SJ, Chu NS. Cerebral hemodynamic responses to betel chewing: a Doppler study. Clin Neuropharmacol. 2002 Sep-Oct;25(5):244-50. doi: 10.1097/00002826-200209000-00003.

    PMID: 12410054BACKGROUND
  • Little, M. A., & Papke, R. L. (2015). Betel, the orphan addiction. J Addict Res Ther, 6(3), 130-132.

    BACKGROUND
  • Lopez-Vilchez MA, Seidel V, Farre M, Garcia-Algar O, Pichini S, Mur A. Areca-nut abuse and neonatal withdrawal syndrome. Pediatrics. 2006 Jan;117(1):e129-31. doi: 10.1542/peds.2005-0281. Epub 2005 Dec 15.

    PMID: 16361222BACKGROUND
  • Lu CT, Yen YY, Ho CS, Ko YC, Tsai CC, Hsieh CC, Lan SJ. A case-control study of oral cancer in Changhua County, Taiwan. J Oral Pathol Med. 1996 May;25(5):245-8. doi: 10.1111/j.1600-0714.1996.tb01379.x.

    PMID: 8835822BACKGROUND
  • Maling TH & Doss JG. (2016). The impact of an intervention programme on oral cancer awareness, health beliefs and practice of preventive behaviour in high-risk Sarawakian indigenous communities. [Doctoral dissertation, Universiti Malaya]

    BACKGROUND
  • Mall ASK, Bhagyalaxmi A. An Informal School-based, Peer-led Intervention for Prevention of Tobacco Consumption in Adolescence: A Cluster Randomized Trial in Rural Gandhinagar. Indian J Community Med. 2017 Jul-Sep;42(3):143-146. doi: 10.4103/ijcm.IJCM_25_16.

    PMID: 28852276BACKGROUND
  • Marewski JN, Gigerenzer G. Heuristic decision making in medicine. Dialogues Clin Neurosci. 2012 Mar;14(1):77-89. doi: 10.31887/DCNS.2012.14.1/jmarewski.

    PMID: 22577307BACKGROUND
  • Miles, D. (2019). ARTICLE:

    BACKGROUND
  • Lee CH, Ko AM, Warnakulasuriya S, Yin BL, Sunarjo, Zain RB, Ibrahim SO, Liu ZW, Li WH, Zhang SS, Kuntoro, Utomo B, Rajapakse PS, Warusavithana SA, Razak IA, Abdullah N, Shrestha P, Kwan AL, Shieh TY, Chen MK, Ko YC. Intercountry prevalences and practices of betel-quid use in south, southeast and eastern Asia regions and associated oral preneoplastic disorders: an international collaborative study by Asian betel-quid consortium of south and east Asia. Int J Cancer. 2011 Oct 1;129(7):1741-51. doi: 10.1002/ijc.25809. Epub 2011 Mar 8.

    PMID: 21128235BACKGROUND
  • Moore G, Campbell M, Copeland L, Craig P, Movsisyan A, Hoddinott P, Littlecott H, O'Cathain A, Pfadenhauer L, Rehfuess E, Segrott J, Hawe P, Kee F, Couturiaux D, Hallingberg B, Evans R. Adapting interventions to new contexts-the ADAPT guidance. BMJ. 2021 Aug 3;374:n1679. doi: 10.1136/bmj.n1679.

    PMID: 34344699BACKGROUND
  • Moss J, Kawamoto C, Pokhrel P, Paulino Y, Herzog T. Developing a Betel Quid Cessation Program on the Island of Guam. Pac Asia Inq. 2015 Fall;6(1):144-150.

    PMID: 27057560BACKGROUND
  • Murphy KL, Liu M, Herzog TA. The Reasons for Betel Quid Chewing Scale (RBCS) for Ex-Chewers: Assessment of Factor Structure, Reliability, Validity and Measurement Invariance across Gender in a Guamanian Sample. Subst Use Misuse. 2022;57(4):522-530. doi: 10.1080/10826084.2021.2019781. Epub 2022 Jan 22.

    PMID: 35067173BACKGROUND
  • Nair J, Ohshima H, Friesen M, Croisy A, Bhide SV, Bartsch H. Tobacco-specific and betel nut-specific N-nitroso compounds: occurrence in saliva and urine of betel quid chewers and formation in vitro by nitrosation of betel quid. Carcinogenesis. 1985 Feb;6(2):295-303. doi: 10.1093/carcin/6.2.295.

    PMID: 3971493BACKGROUND
  • National Institutes of Health (NIH), United States Department of Health and Human Services (2022, July 14). Research Methods Resources. Parallel Group- or Cluster-Randomized Trials (GRTs). https://researchmethodsresources.nih.gov/methods/grt

    BACKGROUND
  • Ogunkolade WB, Boucher BJ, Bustin SA, Burrin JM, Noonan K, Mannan N, Hitman GA. Vitamin D metabolism in peripheral blood mononuclear cells is influenced by chewing "betel nut" (Areca catechu) and vitamin D status. J Clin Endocrinol Metab. 2006 Jul;91(7):2612-7. doi: 10.1210/jc.2005-2750. Epub 2006 May 2.

    PMID: 16670168BACKGROUND
  • Pankaj, C. (2010). Areca nut or betel nut control is mandatory if India wants to reduce the burden of cancer especially cancer of the oral cavity. Int J Head Neck Surg, 1(1), 17-20.

    BACKGROUND
  • Papke RL, Hatsukami DK, Herzog TA. Betel Quid, Health, and Addiction. Subst Use Misuse. 2020;55(9):1528-1532. doi: 10.1080/10826084.2019.1666147. No abstract available.

    PMID: 32569542BACKGROUND
  • Park YB, Jeon SM, Byun SJ, Kim HS, Choi MS. Absorption of intestinal free cholesterol is lowered by supplementation of Areca catechu L. extract in rats. Life Sci. 2002 Mar 8;70(16):1849-59. doi: 10.1016/s0024-3205(02)01485-6.

    PMID: 12005171BACKGROUND
  • Paulino YC, Wilkens LR, Sotto PP, Franke AA, Kawamoto CT, Chennaux JSN, Mendez AJ, Tenorio LF, Badowski G, Pokhrel P, Herzog TA. Rationale and design of a randomized, controlled, superiority trial on areca nut/betel quid cessation: The Betel Nut Intervention Trial (BENIT). Contemp Clin Trials Commun. 2020 Feb 21;17:100544. doi: 10.1016/j.conctc.2020.100544. eCollection 2020 Mar.

    PMID: 32154430BACKGROUND
  • Peng KP, Chiou JF, Chen YT, Liu TZ. Is the blood donated by habitual nut quid chewers suitable for use in transfusion? J Formos Med Assoc. 2010 Feb;109(2):106-12. doi: 10.1016/S0929-6646(10)60030-7.

    PMID: 20206834BACKGROUND
  • Raja M, Saha S, Mohd S, Narang R, Reddy LV, Kumari M. Cognitive Behavioural Therapy versus Basic Health Education for Tobacco Cessation among Tobacco Users: A Randomized Clinical Trail. J Clin Diagn Res. 2014 Apr;8(4):ZC47-9. doi: 10.7860/JCDR/2014/8015.4279. Epub 2014 Apr 15.

    PMID: 24959516BACKGROUND
  • Senn M, Baiwog F, Winmai J, Mueller I, Rogerson S, Senn N. Betel nut chewing during pregnancy, Madang province, Papua New Guinea. Drug Alcohol Depend. 2009 Nov 1;105(1-2):126-31. doi: 10.1016/j.drugalcdep.2009.06.021. Epub 2009 Aug 7.

    PMID: 19665325BACKGROUND
  • Shirzaiy, M., & Neshat, F. (2020). Effect of areca nut on oral health: A review. Journal of Research in Dental and Maxillofacial Sciences, 5(3), 1-6.

    BACKGROUND
  • Siddiqi K, Dogar O, Rashid R, Jackson C, Kellar I, O'Neill N, Hassan M, Ahmed F, Irfan M, Thomson H, Khan J. Behaviour change intervention for smokeless tobacco cessation: its development, feasibility and fidelity testing in Pakistan and in the UK. BMC Public Health. 2016 Jun 10;16:501. doi: 10.1186/s12889-016-3177-8.

    PMID: 27287429BACKGROUND
  • Song H, Wan Y, Xu YY. Betel quid chewing without tobacco: a meta-analysis of carcinogenic and precarcinogenic effects. Asia Pac J Public Health. 2015 Mar;27(2):NP47-57. doi: 10.1177/1010539513486921. Epub 2013 May 10.

    PMID: 23666841BACKGROUND
  • Sotto PP, Mendez AJ, Herzog TA, Cruz C, Chennaux JSN, Legdesog C, Paulino YC. Barriers to Quitting Areca Nut Consumption and Joining a Cessation Program as Perceived by Chewer and Nonchewer Populations in Guam. Subst Use Misuse. 2020;55(6):947-953. doi: 10.1080/10826084.2020.1716012. Epub 2020 Jan 24.

    PMID: 31973623BACKGROUND
  • Strickland SS, Duffield AE. Anthropometric status and resting metabolic rate in users of the areca nut and smokers of tobacco in rural Sarawak. Ann Hum Biol. 1997 Sep-Oct;24(5):453-74. doi: 10.1080/03014469700005212.

    PMID: 9300122BACKGROUND
  • Strickland SS, Veena GV, Houghton PJ, Stanford SC, Kurpad AV. Areca nut, energy metabolism and hunger in Asian men. Ann Hum Biol. 2003 Jan-Feb;30(1):26-52. doi: 10.1080/03014460210157448.

    PMID: 12519653BACKGROUND
  • Szumilas M. Explaining odds ratios. J Can Acad Child Adolesc Psychiatry. 2010 Aug;19(3):227-9. No abstract available.

    PMID: 20842279BACKGROUND
  • Tahir ZH, Doss JG & Jaafar N. (2003). High-risk habits in relation to oral cancer in a Bajau community. [Master's thesis, Universiti Malaya]

    BACKGROUND
  • Taylor RF, al-Jarad N, John LM, Conroy DM, Barnes NC. Betel-nut chewing and asthma. Lancet. 1992 May 9;339(8802):1134-6. doi: 10.1016/0140-6736(92)90732-i.

    PMID: 1349367BACKGROUND
  • Tham J, Sem G, Sit E, Tai MC. The ethics of betel nut consumption in Taiwan. J Med Ethics. 2017 Nov;43(11):739-740. doi: 10.1136/medethics-2016-103990. Epub 2017 Mar 6.

    PMID: 28265049BACKGROUND
  • Tsai JF, Jeng JE, Chuang LY, Ho MS, Ko YC, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY, Yu ML, Dai CY, Ho C. Habitual betel quid chewing as a risk factor for cirrhosis: a case-control study. Medicine (Baltimore). 2003 Sep;82(5):365-72. doi: 10.1097/01.md.0000090401.56130.59.

    PMID: 14530785BACKGROUND
  • Warnakulasuriya S, Trivedy C, Peters TJ. Areca nut use: an independent risk factor for oral cancer. BMJ. 2002 Apr 6;324(7341):799-800. doi: 10.1136/bmj.324.7341.799. No abstract available.

    PMID: 11934759BACKGROUND
  • Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P; ISPOR Task Force for Translation and Cultural Adaptation. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005 Mar-Apr;8(2):94-104. doi: 10.1111/j.1524-4733.2005.04054.x.

    PMID: 15804318BACKGROUND
  • Winstock AR, Trivedy CR, Warnakulasuriya KA, Peters TJ. A dependency syndrome related to areca nut use: some medical and psychological aspects among areca nut users in the Gujarat community in the UK. Addict Biol. 2000 Apr 1;5(2):173-9. doi: 10.1080/13556210050003766.

    PMID: 20575832BACKGROUND
  • Winstock A. Areca nut-abuse liability, dependence and public health. Addict Biol. 2002 Jan;7(1):133-8. doi: 10.1080/13556210120091509.

    PMID: 11900633BACKGROUND
  • Wong, T. Y., Jin, Y. T., Chen, H. O., & Lin, L. M. (1992). Studies on Taiwan betel quid carcinogenicity in hamster cheek pouch. Chin Dent J, 11(4), 155-162.

    BACKGROUND
  • IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Betel-quid and areca-nut chewing and some areca-nut derived nitrosamines. IARC Monogr Eval Carcinog Risks Hum. 2004;85:1-334. No abstract available.

    PMID: 15635762BACKGROUND
  • Yap SF, Ho PS, Kuo HC, Yang YH. Comparing factors affecting commencement and cessation of betel quid chewing behavior in Taiwanese adults. BMC Public Health. 2008 Jun 5;8:199. doi: 10.1186/1471-2458-8-199.

    PMID: 18533044BACKGROUND
  • Yusoff MSB. (2019). ABC of content validation and content validity index calculation. Education in Medicine Journal, 11(2):49-54.

    BACKGROUND
  • Zain, R. B., Fukano, F., Razak, I. A., Shanmuhasuntharam, P., Ikeda, N., & Rahman, Z. A. A. (1999). Risk factors for oral leukoplakia: a comparison of two ethnic groups in Malaysia. Oral oncology, 6, 207-10.

    BACKGROUND

MeSH Terms

Conditions

Tobacco Use Cessation

Condition Hierarchy (Ancestors)

Health BehaviorBehavior

Study Officials

  • Jennifer Geraldine Doss, PhD

    Universiti Malaya

    STUDY CHAIR
  • Amer Siddiq Amer Nordin, PhD

    Universiti Malaya

    STUDY DIRECTOR
  • Mary Melissa Sarimuthu, MCOH

    Universiti Malaya

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Mary Melissa Sarimuthu, MCOH

CONTACT

Jennifer Geraldine Doss, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 12, 2023

First Posted

March 23, 2023

Study Start

January 2, 2024

Primary Completion

June 30, 2024

Study Completion

December 31, 2024

Last Updated

December 6, 2023

Record last verified: 2023-11

Data Sharing

IPD Sharing
Will not share

Locations